FibroGen, Inc (FGEN): Price and Financial Metrics

FibroGen, Inc (FGEN): $13.82

0.33 (+2.45%)

POWR Rating

Component Grades













Add FGEN to Watchlist
Sign Up

Industry: Biotech


of 459

in industry


  • Quality is the dimension where FGEN ranks best; there it ranks ahead of 85.95% of US stocks.
  • FGEN's strongest trending metric is Sentiment; it's been moving up over the last 163 days.
  • FGEN ranks lowest in Momentum; there it ranks in the 9th percentile.

FGEN Stock Summary

  • With a year-over-year growth in debt of 145.61%, Fibrogen Inc's debt growth rate surpasses 93.04% of about US stocks.
  • Revenue growth over the past 12 months for Fibrogen Inc comes in at 137.87%, a number that bests 94.98% of the US stocks we're tracking.
  • The volatility of Fibrogen Inc's share price is greater than that of 94.16% US stocks with at least 200 days of trading history.
  • If you're looking for stocks that are quantitatively similar to Fibrogen Inc, a group of peers worth examining would be ACET, BBIO, SLDB, CCCC, and ONCT.
  • Visit FGEN's SEC page to see the company's official filings. To visit the company's web site, go to

FGEN Valuation Summary

  • In comparison to the median Healthcare stock, FGEN's price/sales ratio is 44.49% lower, now standing at 6.3.
  • FGEN's EV/EBIT ratio has moved up 43.1 over the prior 83 months.
  • Over the past 83 months, FGEN's price/earnings ratio has gone up 29.6.

Below are key valuation metrics over time for FGEN.

Stock Date P/S P/B P/E EV/EBIT
FGEN 2021-08-31 6.3 4.1 -4.7 -3.6
FGEN 2021-08-30 6.2 4.1 -4.6 -3.6
FGEN 2021-08-27 6.2 4.1 -4.6 -3.6
FGEN 2021-08-26 6.2 4.1 -4.6 -3.5
FGEN 2021-08-25 6.4 4.2 -4.8 -3.7
FGEN 2021-08-24 6.5 4.3 -4.8 -3.8

FGEN Growth Metrics

    The 3 year cash and equivalents growth rate now stands at -44.89%.
  • Its 2 year cash and equivalents growth rate is now at -81.55%.
  • Its 5 year cash and equivalents growth rate is now at -17.98%.
FGEN's revenue has moved up $168,693,000 over the prior 49 months.

The table below shows FGEN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 283.765 -34.5 -214.579
2021-06-30 171.824 -80.104 -231.373
2021-03-31 190.348 96.104 -182.698
2020-12-31 176.319 81.602 -189.291
2020-09-30 119.295 43.78 -228.78
2020-06-30 108.437 17.646 -311.223

FGEN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • FGEN has a Quality Grade of B, ranking ahead of 75.49% of graded US stocks.
  • FGEN's asset turnover comes in at 0.212 -- ranking 192nd of 681 Pharmaceutical Products stocks.
  • CKPT, ARWR, and IBIO are the stocks whose asset turnover ratios are most correlated with FGEN.

The table below shows FGEN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.212 0.934 -1.182
2021-03-31 0.235 0.941 -0.907
2020-12-31 0.216 0.950 -0.594
2020-09-30 0.145 0.940 -0.473
2020-06-30 0.128 0.952 -0.520
2020-03-31 0.295 0.992 -0.151

FGEN Price Target

For more insight on analysts targets of FGEN, see our FGEN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $24.71 Average Broker Recommendation 1.9 (Hold)

FGEN Stock Price Chart Interactive Chart >

Price chart for FGEN

FGEN Price/Volume Stats

Current price $13.82 52-week high $57.21
Prev. close $13.49 52-week low $9.88
Day low $13.29 Volume 3,796,000
Day high $14.19 Avg. volume 1,124,150
50-day MA $13.61 Dividend yield N/A
200-day MA $16.05 Market Cap 1.28B

FibroGen, Inc (FGEN) Company Bio

Fibrogen is a research-based biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics to treat serious unmet medical needs. The company was incorporated in 1993 and is based in San Francisco, California.

FGEN Latest News Stream

Event/Time News Detail
Loading, please wait...

FGEN Latest Social Stream

Loading social stream, please wait...

View Full FGEN Social Stream

Latest FGEN News From Around the Web

Below are the latest news stories about Fibrogen Inc that investors may wish to consider to help them evaluate FGEN as an investment opportunity.

Woodstock Corp Buys Amgen Inc, Applied Materials Inc, FedEx Corp, Sells Reata Pharmaceuticals ...

Boston, MA, based Investment company Woodstock Corp (Current Portfolio) buys Amgen Inc, Applied Materials Inc, FedEx Corp, Southwestern Energy Co, Sun Life Financial Inc, sells Reata Pharmaceuticals Inc, Aldeyra Therapeutics Inc, Epizyme Inc, International Business Machines Corp, Omnicom Group Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Woodstock Corp.

Yahoo | January 7, 2022

FibroGen to Present at H.C. Wainwright Bioconnect Virtual Conference

SAN FRANCISCO, Jan. 04, 2022 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright Bioconnect Virtual Conference taking place January 10-13. The on-demand webcast of the session will be available on January 10 at 7:00am EST. The audio webcast of the event will be available on the “Events & Presentations” section of the FibroGen Investor webpage at A replay will

Yahoo | January 4, 2022

Does FibroGen (NASDAQ:FGEN) Have A Healthy Balance Sheet?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Yahoo | January 1, 2022

FibroGen Exercises Exclusive License Option for HiFiBiO’s CCR8 Program

Exclusive license to anti-CCR8 monoclonal antibody program further strengthens FibroGen’s preclinical development pipelineHiFiBiO to receive $35 million option exercise payment, potential milestones and royalties SAN FRANCISCO and CAMBRIDGE, Mass., Dec. 20, 2021 (GLOBE NEWSWIRE) -- FibroGen, Inc. (Nasdaq: FGEN), a leading biopharmaceutical company discovering, developing, and commercializing first-in-class therapeutics, and HiFiBiO Therapeutics, a private, multinational clinical-stage biotherape

Yahoo | December 20, 2021

A Quick Glance At FibroGen Inc. (NASDAQ: FGEN) Stock: It Is up 33.11% From Its 52-Week Low; YTD, It Is Down -60.18 Percent

During the last session, FibroGen Inc. (NASDAQ:FGEN)s traded shares were 7.55 million, with the beta value of the company hitting 0.88. At the end of the trading day, the stocks price was $14.77, reflecting an intraday gain of 5.50% or $0.77. The 52-week high for the FGEN share is $57.21, that puts it down -287.34 A Quick Glance At FibroGen Inc. (NASDAQ: FGEN) Stock: It Is up 33.11% From Its 52-Week Low; YTD, It Is Down -60.18 Percent Read More »

Marketing Sentinel | December 18, 2021

Read More 'FGEN' Stories Here

FGEN Price Returns

1-mo -10.20%
3-mo 27.26%
6-mo 5.66%
1-year -70.94%
3-year -73.38%
5-year -42.66%
YTD -1.99%
2021 -61.98%
2020 -13.52%
2019 -7.32%
2018 -2.36%
2017 121.50%

Continue Researching FGEN

Here are a few links from around the web to help you further your research on Fibrogen Inc's stock as an investment opportunity:

Fibrogen Inc (FGEN) Stock Price | Nasdaq
Fibrogen Inc (FGEN) Stock Quote, History and News - Yahoo Finance
Fibrogen Inc (FGEN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8571 seconds.